SCHEMBL4735638

SCHEMBL4735638

COc1nc(=O)[nH]c2ccccc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.53
KDM4E B2RXH2 5/20 0.53
HPGD P15428 4/20 0.53
HSD17B10 Q99714 2/20 0.53
TSHR P16473 1/20 0.53
ADORA3 P0DMS8 3/20 0.50
APP P05067 4/20 0.48
PDE3B Q13370 1/20 0.47
PDE3A Q14432 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.46
BTK Q06187 1/20 0.46
ABCG2 Q9UNQ0 2/20 0.45
LMNA P02545 2/20 0.44
CYP1A2 P05177 2/20 0.44
CYP2C19 P33261 2/20 0.44
GLA P06280 1/20 0.44
GAA P10253 1/20 0.44
HTT P42858 1/20 0.44
ATM Q13315 1/20 0.44
MEN1 O00255 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28329925 0.82 ALDH1A1 (0.46) ALDH1A1KDM4EHPGDHSD17B10TSHR
SCHEMBL1622369 0.81 KDM4E (0.53) ALDH1A1KDM4EHPGDHSD17B10TSHR
SCHEMBL357339 0.80 GSK3B (0.49) ALDH1A1KDM4EHPGDHSD17B10TSHR
SCHEMBL15846341 0.78 KDM4E (0.53) ALDH1A1KDM4EHPGDHSD17B10TSHR
SCHEMBL7998448 0.78 KDM4E (0.56) ALDH1A1KDM4EHPGDHSD17B10TSHR
SCHEMBL530191 0.76 ALDH1A1 (0.58) ALDH1A1KDM4EHPGDHSD17B10TSHR
SCHEMBL30293081 0.76 ALDH1A1 (0.58) ALDH1A1KDM4EHPGDHSD17B10TSHR
SCHEMBL1621890 0.75 APP (0.56) ALDH1A1KDM4EHPGDHSD17B10TSHR
SCHEMBL4737616 0.75 ABCG2 (0.53) ALDH1A1KDM4EHPGDPDE3BPDE3A
SCHEMBL3239485 0.75 NQO2 (0.53) ALDH1A1KDM4EHPGDTSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9656971-B2 COMT inhibitors HOFFMANN-LA ROCHE INC. (US) 2017-05-23 US disclosed
EP-2938600-B1 COMT INHIBITORS HOFFMANN LA ROCHE (CH) 2017-01-25 EP disclosed
US-20160002177-A1 COMT INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2016-01-07 US disclosed
EP-2938600-A1 COMT INHIBITORS F. Hoffmann-La Roche AG (CH) 2015-11-04 EP disclosed
WO-2014102233-A1 COMT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2014-07-03 WO disclosed
WO-2008067219-A2 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2008-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160002177-A1 COMT INHIBITORS COMT, PNMT, SLC6A3 ALDH1A1 92/4885KDM4E 1308/4885HPGD 1160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.